Andrew A. Lane, MD, PhD

AMPK activation induces immunogenic cell death in AML. Blood Adv. 2023 Dec 26; 7(24):7585-7596. View in: Pubmed

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2023 Dec 05. View in: Pubmed

Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow. Mod Pathol. 2023 Oct 13; 37(1):100352. View in: Pubmed

DDX41: here, there…and everywhere. Blood. 2023 10 05; 142(14):1177-1178. View in: Pubmed

Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581. View in: Pubmed

Enhancing dendritic cells by inhibiting BCL2. Trends Cancer. 2023 Dec; 9(12):987-988. View in: Pubmed

Leukemia circulation kinetics revealed through blood exchange method. bioRxiv. 2023 Sep 05. View in: Pubmed

Loss of chromosome Y in primary tumors. Cell. 2023 Jun 22. View in: Pubmed

Genomics of PDGFR-rearranged hypereosinophilic syndrome. Blood Adv. 2023 06 13; 7(11):2558-2563. View in: Pubmed

Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023 Jun; 618(7966):834-841. View in: Pubmed

False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay. Acta Haematol. 2023; 146(4):316-321. View in: Pubmed

Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells. Am J Clin Pathol. 2023 05 02; 159(5):455-463. View in: Pubmed

Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2023 Mar 23. View in: Pubmed

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578. View in: Pubmed

Novel use of acitretin for posttransplant Grover's disease and cutaneous graft versus host disease. JAAD Case Rep. 2023 Mar; 33:67-69. View in: Pubmed

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 09 10; 40(26):3032-3036. View in: Pubmed

Peripheral blood CD3+ T-cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. Br J Haematol. 2022 10; 199(1):100-105. View in: Pubmed

Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma. 2022 11; 63(11):2757-2759. View in: Pubmed

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11). View in: Pubmed

Shared Clonal Origin of Multiple Histiocytic and Dendritic Neoplasms and Polycythemia Vera, Follicular Lymphoma in 1 Patient. Am J Dermatopathol. 2022 12 01; 44(12):929-932. View in: Pubmed

CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2022 May 03; 14(9). View in: Pubmed

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun. 2022 04 28; 13(1):2228. View in: Pubmed

Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 08; 63(8):1934-1941. View in: Pubmed

Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm. Front Immunol. 2022; 13:809414. View in: Pubmed

Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations. Nat Biotechnol. 2022 07; 40(7):1030-1034. View in: Pubmed

AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Rep. 2022 01 04; 38(1):110197. View in: Pubmed

Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discov. 2022 02; 12(2):522-541. View in: Pubmed

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480. View in: Pubmed

Targeting CD123 in AML. Clin Lymphoma Myeloma Leuk. 2020 09; 20 Suppl 1:S67-S68. View in: Pubmed

Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. Leuk Lymphoma. 2020 09; 61(9):2258-2261. View in: Pubmed

Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020 03 24; 4(6):1006-1011. View in: Pubmed

Blastic Plasmacytoid Dendritic Cell Neoplasm in 2020 and Beyond. Hematol Oncol Clin North Am. 2020 06; 34(3):xiii-xiv. View in: Pubmed

Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am. 2020 06; 34(3):589-600. View in: Pubmed

Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat Commun. 2020 03 16; 11(1):1406. View in: Pubmed

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 11 01; 129(11):5005-5019. View in: Pubmed

Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Rev Clin Pharmacol. 2019 Oct; 12(10):941-946. View in: Pubmed

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 08 22; 134(8):678-687. View in: Pubmed

Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):545-554. View in: Pubmed

Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. J Glob Oncol. 2019 06; 5:1-6. View in: Pubmed

Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508. View in: Pubmed

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637. View in: Pubmed

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Res. 2019 06; 29(6):446-459. View in: Pubmed

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. Cell. 2019 03 07; 176(6):1265-1281.e24. View in: Pubmed

More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med. 2019 02 14; 380(7):695-6. View in: Pubmed

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Curr Hematol Malig Rep. 2018 12; 13(6):581-587. View in: Pubmed

Trisomy of a Down Syndrome Critical Region Globally Amplifies Transcription via HMGN1 Overexpression. Cell Rep. 2018 11 13; 25(7):1898-1911.e5. View in: Pubmed

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. 2017 12; 12(6):592-597. View in: Pubmed

Monogenic Hashimoto thyroiditis associated with a variant in the thyroglobulin (TG) gene. J Autoimmun. 2018 01; 86:116-119. View in: Pubmed

Maternal iAMP21 acute lymphoblastic leukemia detected on prenatal cell-free DNA genetic screening. Blood Adv. 2017 Aug 22; 1(19):1491-1494. View in: Pubmed

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017 04 21; 356(6335). View in: Pubmed

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164. View in: Pubmed

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep. 2016 12; 11(6):462-467. View in: Pubmed

Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16. View in: Pubmed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. View in: Pubmed

Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):1046-1053. View in: Pubmed

Mutations in G protein ß subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan; 21(1):71-5. View in: Pubmed

Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Stem Cell Reports. 2014 Nov 11; 3(5):832-40. View in: Pubmed

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8. View in: Pubmed

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23. View in: Pubmed

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6. View in: Pubmed

Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 2013 May 24; 3:e117. View in: Pubmed

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71. View in: Pubmed

Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One. 2012; 7(11):e49201. View in: Pubmed

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73. View in: Pubmed

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma. 2012 Jun; 53(6):1130-6. View in: Pubmed

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55. View in: Pubmed

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma. Leuk Lymphoma. 2011 Jul; 52(7):1363-6. View in: Pubmed

Stem cells and DNA damage: persist or perish? Cell. 2010 Aug 06; 142(3):360-2. View in: Pubmed

A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood. 2010 Nov 04; 116(18):3604-10. View in: Pubmed

von Willebrand disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy. Am J Hematol. 2010 Feb; 85(2):134-5. View in: Pubmed

Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10; 27(32):5459-68. View in: Pubmed

Acute myeloid leukemia in first complete remission: How do we select patients for allogeneic stem cell transplantation?. American Journal of Hematology/Oncology. 2009; 8(10):508-511. View in: Pubmed

Pathogenesis of acute promyelocytic leukemia [dissertation]. 2006. View in: Pubmed

Murine acute promyelocytic leukemia cells can be recognized and cleared in vivo by adaptive immune mechanisms. Haematologica. 2005 Aug; 90(8):1042-9. View in: Pubmed

Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells. Mol Cell Biol. 2005 Jan; 25(1):23-33. View in: Pubmed

Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol. 2004 Dec; 24(24):10882-93. View in: Pubmed

Neutrophil elastase cleaves PML-RARalpha and is important for the development of acute promyelocytic leukemia in mice. Cell. 2003 Oct 31; 115(3):305-18. View in: Pubmed

High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood. 2003 Sep 01; 102(5):1857-65. View in: Pubmed

Mouse models of acute promyelocytic leukemia. Curr Opin Hematol. 2001 Jul; 8(4):206-11. View in: Pubmed

Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphavbeta3 and alpha5beta1 integrins. EMBO J. 1999 Apr 15; 18(8):2165-73. View in: Pubmed

Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev. 1998 Mar 01; 12(5):667-78. View in: Pubmed

Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase. J Biol Chem. 1998 Jan 16; 273(3):1303-8. View in: Pubmed